noom with glp 1 offers cut-price compounded GLP-1 drug for obesity Why We Launched Noom GLP-1RX

Qualifying criteria include BMI greater than 27 with prediabetes or established cardiovascular disease, or BMI over 30 with uncontrolled hypertension, advanced kidney disease, or heart failure

Yoshida K, Solomon DH, Kim SC

doi: 10.1002/brb3.70661

With respect to GLP-1RAs, liraglutide and semaglutide have demonstrated a reduction in the risk of major adverse cardiovascular events (MACE) [16, 17], and, while yet not published, early reports for dulaglutide indicate CV benefits in patients with a wide range of CV risk [18]

Clinical trials reveal that up to 39% of weight lost on GLP-1 therapy comes from lean muscle mass rather than fat